Jose L. Rivas

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine · 2022 · 1.5K citations · Full text

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Christina Charles‐Schoeman, Maya H Buch, Maxime Dougados et al. · Annals of the Rheumatic Diseases · 2022 · 182 citations · Full text

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

Joel M. Kremer, Clifton O. Bingham, Laura C. Cappelli et al. · ACR Open Rheumatology · 2021 · 135 citations · Full text

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Lars Erik Kristensen, Silvio Danese, Arne Yndestad et al. · Annals of the Rheumatic Diseases · 2023 · 108 citations · Full text

Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Jose L. Rivas, Teresa Palencia, Guerau Fernández et al. · Frontiers in Immunology · 2018 · 62 citations · Full text